Helping European Biotechs Accelerate Early Phase Success With Faster Timelines, Lower Costs, and Globally Accepted Data
ADELAIDE, Australia, Nov. 03, 2025, the largest premium full-service Australian headquartered CRO with more than 30 years of early phase expertise, is highlighting its Early Phase Center of Excellence for Biotechsand the well-established Australian Advantageto European biotechs ahead of BIO-Europe in Vienna, November 3-5, 2025.
European biotechs under increasing investor and regulatory pressure are turning to Avance Clinical's proven Australian pathway to achieve first-in-human (FIH) and early proof-of-concept studies with:
- Startup timelines in as little as 5-6 weeks from final protocol to study approval through Australia's streamlined regulatory frameworks (CTN/CTA) and Avance Clinical's deep early phase expertise
- Globally accepted trial data, recognized by EMA, FDA, and other regulators
- Up to 43.5% cash rebate through Australia's R&D tax incentive program
- Seamless progression to global trials through Avance Clinical's GlobalReady program and worldwide partner network of 2,000+ sites
"EU biotechs are often surprised to learn just how efficient Australia is for early phase research," said Mark Harvill, CEO of Avance Clinical. "Our new Early Phase Center of Excellence for Biotechs underscores our commitment to scientific rigor, innovation, and helping sponsors reach critical milestones faster - without compromising quality."
Avance Clinical has guided more than 710 emerging biotechs across 250+ therapeutic indications, supported by in-house scientific and regulatory affairs expertise, and best-in-class clinical operations. Its dedicated Early Phase Center of Excellence for Biotechs was designed specifically to meet the needs of international biotech sponsors navigating complex first-in-human and early development studies.
"With growing competition in biotech, speed and quality in early development are critical," said Ben Edwards, Chief Operating Officerof Avance Clinical. "By combining the Australian Advantage, which offers up to 43.5% Australian Government R&D tax rebate, with our deep early phase expertise, EU sponsors can de-risk their programs and maintain capital efficiency while advancing quickly to global markets."
Meet Avance Clinical at BIO-Europe Vienna
European biotechs attending BIO-Europe 2025 are invited to meet with Liahna Toy, Vice President, Commercial Business Development, and Dewald Jacobs, Director of Business Development, at Booth C185 at the Vienna Congress & Convention Center (Messe Wien), November 3-5, 2025.
This is a unique opportunity for EU sponsors to discuss how Avance Clinical's early phase expertise and the Australian Advantage can accelerate development pipelines.
Book a Meeting Now
About Avance Clinical
Avance Clinical is the largest premium full-service Australian headquartered CRO delivering high-quality clinical trials in Australia, New Zealand, Asia, North America, and Europe for international biotechs. The company has won multiple Frost & Sullivan CRO Market Leadership and Customer Value Leadership Awards.
With over 30 years of experience and cross-therapeutic expertise in more than 250 indications, Avance Clinical provides services from pre-clinical to late-phase trials, supported by best-in-class regulatory, clinical, and operational teams.
Find out more:
- Visit our website and submit a request for proposal: www.avancecro.com (http://www.avancecro.com)
- Discover the Australian Advantage (https://www.avancecro.com/the-australian-advantage/)
- Learn about our Early Phase Center of Excellence (https://www.avancecro.com/early-phase-center-of-excellence-for-biotechs/)
- Book a meeting with our expert team (https://www.avancecro.com/events/meet-avance-clinical-at-bio%e2%80%91europe-2025-in-vienna-austria/)
- Find out more about the EU Advantage (https://www.avancecro.com/the-eu-advantage/)
CONTACT:
Gabe Martinez
Director Content, Media, & PR
308-237-5567
Pr@scorrmarketing.com
A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/6bdfcdd6-822b-4af9-aa9a-832fc449ca24
